Abstract
While genes and RNA encode information about cellular status, proteins are considered the engine of the cellular machine, as they are the effective elements that drive all cellular functions including proliferation, migration, differentiation, and apoptosis. Consequently, investigations of the cellular protein network are considered a fundamental tool for understanding cellular functions.
Alteration of the cellular homeostasis driven by elaborate intra- and extracellular interactions has become one of the most studied fields in the era of personalized medicine and targeted therapy. Increasing interest has been focused on developing and improving proteomic technologies that are suitable for analysis of clinical samples. In this context, reverse-phase protein microarrays (RPPA) is a sensitive, quantitative, high-throughput immunoassay for protein analyses of tissue samples, cells, and body fluids.
RPPA is well suited for broad proteomic profiling and is capable of capturing protein activation as well as biochemical reactions such as phosphorylation, glycosylation, ubiquitination, protein cleavage, and conformational alterations across hundreds of samples using a limited amount of biological material. For these reasons, RPPA represents a valid tool for protein analyses and generates data that help elucidate the functional signaling architecture through protein-protein interaction and protein activation mapping for the identification of critical nodes for individualized or combinatorial targeted therapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Liotta LA, Espina V, Mehta AI et al (2003) Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 3:317–325
Paweletz CP, Charboneau L, Bichsel VE et al (2001) Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20:1981–1989
Gallagher RI, Silvestri A, Petricoin EF 3rd et al (2011) Reverse phase protein microarrays: fluorometric and colorimetric detection. Methods Mol Biol 723:275–301
Pierobon M, Wulfkuhle J, Liotta L et al (2015) Application of molecular technologies for phosphoproteomic analysis of clinical samples. Oncogene 12:805–814
VanMeter AJ, Rodriguez AS, Bowman ED et al (2008) Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics 7:1902–1924
Rapkiewicz A, Espina V, Zujewski JA et al (2007) The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology. Cancer 111:173–184
Wulfkuhle JD, Berg D, Wolff C et al (2012) Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clin Cancer Res 18:6426–6435
Kornblau SM, Tibes R, Qiu Y et al (2009) Functional proteomic profiling of AML predicts response and survival. Blood 113(1):154–164
Silvestri A, Colombatti A, Calvert VS et al (2010) Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing. Lab Investig 90:787–796
Pierobon M, Silvestri A, Spira A et al (2014) A pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with Imatinib and Panitumumab. J Proteome Res 6:2846–2855
Arnedos M, Vicier C, Loi S et al (2015) Precision medicine for metastatic breast cancer-limitations and solutions. Nat Rev Clin Oncol 12:693–704
Yap TA, Yan L, Patnaik A et al (2011) First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29:4688–4695
Chiechi A, Novello C, Magagnoli G et al (2013) Elevated TNFR1 and serotonin in bone metastasis are correlated with poor survival following bone metastasis diagnosis for both carcinoma and sarcoma primary tumors. Clin Cancer Res 1:2473–2485
Baldelli E, Bellezza G, Haura EB et al (2015) Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors. Oncotarget 20:32368–32379
Zupa A, Improta G, Silvestri A et al (2012) A pilot characterization of human lung NSCLC by protein pathway activation mapping. J Thorac Oncol 7:1755–1766
Li J, Lu Y, Akbani R et al (2013) TCPA: a resource for cancer functional proteomics data. Nat Methods 10:1046–1047
Bobrow MN, Harris TD, Shaughnessy KJ et al (1989) Catalyzed reporter deposition, a novel method of signal amplification Application to immunoassays. J Immunol Methods 125:279–285
Boellner S, Becker KF (2015) Recent progress in protein profiling of clinical tissues for next-generation molecular diagnostics. Expert Rev Mol Diagn 15:1277–1292
Nishizuka SS, Mills GB (2016) New era of integrated cancer biomarker discovery using reverse-phase protein arrays. Drug Metab Pharmacokinet 31:35–45
Espina V, Mehta AI, Winters ME et al (2003) Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics 3:2091–2100
Becker KF, Schott C, Hipp S et al (2007) Quantitative protein analysis from formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis. J Pathol 211:370–378
Baldelli E, Haura EB, Crinò L et al (2015) Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: implications for personalized medicine. Proteomics Clin Appl 9:928–937
Mueller C, deCarvalho AC, Mikkelsen T et al (2014) Glioblastoma cell enrichment is critical for analysis of phosphorylated drug targets and proteomic-genomic correlations. Cancer Res 74:818–828
Emmert-Buck MR, Bonner RF, Smith PD et al (1996) Laser capture microdissection. Science 274:998–1001
Bonner RF, Emmert-Buck M, Cole K et al (1997) Laser capture microdissection: molecular analysis of tissue. Science 278:1481, 1483
Grote T, Siwak DR, Fritsche HA et al (2008) Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer. Proteomics 8:3051–3060
Davuluri G, Espina V, Petricoin EF et al (2009) Activated VEGF receptor shed into the vitreous in eyes with wet AMD: a new class of biomarkers in the vitreous with potential for predicting the treatment timing and monitoring response. Arch Ophthalmol 127:613–621
Mueller C, Zhou W, Vanmeter A et al (2010) The Heme degradation pathway is a promising serum biomarker source for the early detection of Alzheimer’s disease. J Alzheimers Dis 19:1081–1091
Pin E, Federici G, Petricoin EF (2014) Preparation and use of reverse protein microarrays. Curr Protoc Protein Sci 75:Unit 27.7
Petricoin EF 3rd, Espina V, Araujo RP et al (2007) Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res 67:3431–3440
Espina V, Wulfkuhle JD, Calvert VS et al (2006) Laser-capture microdissection. Nat Protoc 1:586–603
Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685
Stillman BA, Tonkinson JL (2000) FAST slides: a novel surface for microarrays. BioTechniques 29:630–635
Tonkinson JL, Stillman BA (2002) Nitrocellulose: a tried and true polymer finds utility as a post-genomic substrate. Front Biosci 7:c1–12
Mueller C, Edmiston KH, Carpenter C et al (2011) One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens. PLoS One 6:e23780
Mueller C, Liotta LA, Espina V (2010) Reverse phase protein microarrays advance to use in clinical trials. Mol Oncol 4:461–481
Pierobon M, Gandhi L, Cristofanilli M et al (2016) Protein pathway activation mapping for multiomic based precision medicine. AJHO 12:20–24
King G, Payne S, Walker F et al (1997) A highly sensitive detection method for immunohistochemistry using biotinylated tyramine. J Pathol 183:237–241
Bobrow MN, Shaughnessy KJ, Litt GJ (1991) Catalyzed reporter deposition, a novel method of signal amplification. II. Application to membrane immunoassays. J Immunol Methods 137:103–112
Bobrow MN, Litt GJ, Shaughnessy KJ et al (1992) The use of catalyzed reporter deposition as a means of signal amplification in a variety of formats. J Immunol Methods 150:145–149
Hunyady B, Krempels K, Harta G et al (1996) Immunohistochemical signal amplification by catalyzed reporter deposition and its application in double immunostaining. J Histochem Cytochem 44:1353–1362
Berggren K, Steinberg TH, Lauber WM et al (1999) A luminescent ruthenium complex for ultrasensitive detection of proteins immobilized on membrane supports. Anal Biochem 276:129–143
Berggren KN, Schulenberg B, Lopez MF et al (2002) An improved formulation of SYPRO ruby protein gel stain: comparison with the original formulation and with a ruthenium II tris (bathophenanthroline disulfonate) formulation. Proteomics 2:486–498
Miller WG, Gibbs EL, Jay DW et al (2006) Preparation and testing of reagent water in the clinical laboratory; approved guideline, vol 26, 4th edn. Clinical Laboratory Standards Institute, Wayne, PA
Signore M, Reeder KA (2012) Antibody validation by western blotting. Methods Mol Biol 823:139–155
Rossner M, Yamada KM (2004) What’s in a picture? The temptation of image manipulation. J Cell Biol 166:11–15
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Baldelli, E., Calvert, V., Hodge, A., VanMeter, A., Petricoin, E.F., Pierobon, M. (2017). Reverse Phase Protein Microarrays. In: Espina, V. (eds) Molecular Profiling. Methods in Molecular Biology, vol 1606. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6990-6_11
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6990-6_11
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6989-0
Online ISBN: 978-1-4939-6990-6
eBook Packages: Springer Protocols